Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global leader in the field of analytical instruments and software solutions. For nearly six decades, the company has pioneered advancements in chromatography, mass spectrometry, and thermal analysis, catering to life, materials, and food sciences. Headquartered in Milford, Massachusetts, Waters Corp. operates directly in 35 countries, supported by approximately 8,000 employees and 15 manufacturing facilities globally.
Waters' main business segments include Waters, TA Instruments, VICAM, ERA, and Nonlinear Dynamics. The company's diverse product portfolio features ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), chromatography columns, mass spectrometry systems, and laboratory informatics solutions. These innovations empower laboratory-dependent organizations to achieve advancements in healthcare, environmental management, food safety, and water quality.
Waters Corporation serves a wide array of customers, including biopharmaceutical companies (57% of sales), industrial clients (31% of sales), and academic/government institutions (12% of sales). The company’s products are available in over 100 countries, ensuring a broad market reach.
Recent achievements include the launch of new accessories for TA Instruments Discovery Hybrid Rheometers, designed for battery formulation analysis, and the introduction of Oasis WAX/GCB and GCB/WAX Cartridges for PFAS analysis. These innovations reflect the company’s commitment to addressing emerging scientific challenges and regulatory requirements. Additionally, Waters continues to enhance its mass spectrometry capabilities with products like the ACQUITY QDa II Mass Detector and the Xevo MRT MS, aimed at accelerating research in pharmaceuticals, food, chemicals, and materials.
Financially, Waters Corporation reported first-quarter 2024 sales of $637 million, with a strategic focus on innovation and operational efficiency. Despite a 7% decrease in sales compared to the previous year, the company remains optimistic about future growth, driven by new product launches and higher growth areas.
Waters Corporation stands as a pivotal player in the analytical instruments industry, consistently driving scientific advancements and operational excellence.
Waters Corporation (NYSE:WAT) has partnered with BioInfra to launch the ASEAN Academy for Bioanalysis in South Korea. This training facility aims to equip scientists with essential bioanalytical skills required for drug discovery and development, addressing the increasing demand for low-cost generic drugs in Southeast Asia. The academy will focus on bioequivalence trials, enhancing the region's scientific competitiveness and pharmaceutical research quality, ultimately benefiting the growing elderly population facing health challenges.
Waters Corporation (NYSE:WAT) introduced the Xevo G3 quadrupole time-of-flight mass spectrometer, boasting up to 10X more sensitivity than its predecessor. The launch, announced at the ASMS 2022 Annual Conference, aims to enhance drug discovery and development. Additionally, the new CONFIRM Sequence app streamlines nucleic acid sequencing confirmation, cutting data review time by 50%. Finally, the integration of a new electrospray ionization source with the SELECT SERIES MRT system enables rapid molecular characterization.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will engage in a fireside chat at the Jefferies 2022 Global Healthcare Conference in New York City on June 8th, 2022, at 4:30 PM EST. Interested investors can access the live webcast via Waters' investor relations website, which will be available for replay for 30 days. Waters has been a leader in analytical instruments for over 60 years, operating in 35 countries with a workforce exceeding 7,800 employees.
Waters Corporation (NYSE: WAT) has inaugurated its latest innovation lab, Immerse™ Delaware, at the University of Delaware's STAR campus. This facility aims to tackle major challenges in the biopharmaceutical industry by fostering collaboration between students, faculty, and industry partners. The lab is a product of a multi-year partnership established in October 2021, focusing on improving biotherapeutic development and manufacturing processes.
Waters Corporation (NYSE: WAT) reported first quarter 2022 sales of $691 million, marking a 13% increase year-over-year and a 16% rise in constant currency. Instrument sales surged 26% in constant currency, driven by strong performance across key product lines. The company achieved a GAAP EPS of $2.62 and a non-GAAP EPS of $2.80, reflecting a 22% increase compared to the previous year. Waters raised its 2022 guidance for sales growth to 7.5% to 9% and non-GAAP EPS to $11.90 to $12.10 amid positive customer feedback for new product launches.
Waters Corporation (NYSE:WAT) will host its 2022 Investor Day on May 19, 2022, starting at 8:45 a.m. ET at the New York Stock Exchange in New York, NY. The event includes presentations by senior management and a Q&A session. A live webcast will be available on Waters’ investor relations website, with a replay offered later. Waters Corporation is a leader in analytical instruments and software, serving various scientific fields for over 60 years, operating in 35 countries, and employing over 7,800 people globally.
Waters Corporation (NYSE:WAT) is set to host a live webcast of its Q1 2022 financial results conference call on May 3, 2022, at 8:00 a.m. Eastern Time. Interested parties can access the live presentation via Waters' investor relations website. A replay will be available until May 17, 2022, at midnight Eastern Time. Waters is renowned for its innovations in chromatography, mass spectrometry, and thermal analysis, with over 7,400 employees operating in 35 countries.
Waters Corporation (NYSE:WAT) has launched the Xevo TQ Absolute, advancing mass spectrometry technology. This new tandem quadrupole mass spectrometer is up to 15X more sensitive in quantifying negatively ionized compounds and 45% smaller than its competitors, using 50% less power and nitrogen. Designed for various analytical laboratories, it aims to enhance productivity and support sustainability goals. Shipments are expected to begin in May.
Waters Corporation (NYSE:WAT) has launched the Intact Mass application on the waters_connect platform, enabling faster and simplified biomolecule analysis. This software can confirm the mass and purity of biomolecules nearly twice as fast as existing options. The app is available as an upgrade for new and installed BioAccord LC-MS systems. Additionally, the introduction of Waters MaxPeak Premier columns enhances sensitivity by 2x to 3x compared to conventional steel columns, facilitating effective drug discovery processes.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will participate in a fireside chat at the Cowen Healthcare Conference on March 9, 2022, at 2:10 PM EST. Investors can access the live webcast on Waters’ investor relations website, with a replay available for 30 days. Waters Corporation has been a leader in chromatography, mass spectrometry, and thermal analysis for over 60 years, employing over 7,400 people globally and operating in 35 countries.
FAQ
What is the current stock price of Waters (WAT)?
What is the market cap of Waters (WAT)?
What industries does Waters Corporation serve?
What are some of Waters Corporation's recent product launches?
How does Waters Corporation contribute to scientific advancements?
What is the significance of the TA Instruments Discovery Hybrid Rheometers?
How is Waters Corporation performing financially?
Where is Waters Corporation headquartered?
How many employees does Waters Corporation have?
What are TA Instruments' main products?
What is the significance of the Oasis WAX/GCB Cartridges?
How can I access Waters Corporation's financial results?
